全球视网膜药物市场（2023年）：2022-2028年分析

本报告审视了全球视网膜药物市场，并提供了市场概况，包括未来五年的市场业绩预测、未来主要趋势以及进入市场的 29 家参与者的公司简介。Masu。

内容

• 对视网膜疾病及其危险因素的思考
• 这些疾病的诊断和治疗
• 视网膜医学和视网膜专家的世界观
• 市场上的视网膜药物和生物製剂
• 正在开发的研究药物
• 开发和营销视网膜药物的公司简介以及拥有临床前项目的其他公司名单

What's New:

The "2023 Retinal Pharmaceuticals Market Report" features new sales and disease prevalence forecasts through 2028. The report now covers adoption plans for complement inhibitors and new anti-VEGFs by ophthalmologists in the United States and Western Europe, as well as treatment patterns for anti-VEGFs. In addition, it includes IVT injection shares by drug in the United States and Western Europe.

The new report also evaluates more development-stage categories, therapies, and companies.

The "2023 Retinal Pharmaceuticals Market Report" analyzes the market for the treatment of retinal diseases and discusses important trends and key factors for future market success. It examines the market's evolution and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 29 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

The report explores a variety of topics intended to provide depth and context to the understanding of market dynamics in this ophthalmic segment. Our coverage includes:

• Discussions of retinal diseases and their risk factors.

• Diagnosis and treatment of these diseases.

• A global view of retinal care and retina specialists.

• Retinal pharmaceuticals and biologics in the marketplace.

• Investigational agents in the development pipeline.

• Profiles of companies developing and marketing retinal pharmaceuticals, plus a listing of additional companies with preclinical programs.

The report provides market forecasts for branded ocular anti-VEGFs, cancer drugs used off label, biosimilars, complement inhibitors expected to enter the marketplace within five years, gene therapies, and others. The report also includes a separate forecast for sustained-drug-delivery devices in retina.

The report delves into the development pipelines of 11 categories of retinal pharmaceuticals:

Author Profile:

Peter Downs

Peter Downs has more than 30 years of experience as a business and medical journalist and investigative reporter. He has written for a variety of medical industry publications, including the Medical Business Journal, CBS HealthWatch, and Oncology News International.

Prior to joining Market Scope in 2015 and turning his attention to ophthalmology, Peter analyzed markets for organ and tissue transplantation. Since joining Market Scope, he has traveled to several markets outside the US, including China, Europe, and India, to study ophthalmology at the local level.

In addition to his research and writing efforts on the ophthalmic market, he is also a contributor to Ophthalmic Market Perspectives, the firm's monthly industry newsletter.